Investing Observation & Opinion


  • Economy & Politics
  • Investing
  • Personal Finance
  • Related Posts

    Is The ‘Easy’ Money Over For European Stocks?
    Europe Cracks Down On Bitcoin, Virtual Currencies To “Curb Terrorism Funding”
    For Caterpillar The Depression Has Never Been Worse… But It Has A Cunning Plan How To Deal With It
    A Modest Proposal: All Companies Should Shut Down At Age 18
    Star Wars Could Break Box Office Records After This News
    Leave Bitcoin Alone. Abolish Cash Instead.
    What UnitedHealth Doesn’t Mean For Obamacare
    This Could Be The Next Weapon Of Mass Destruction
    Warren Buffett Stocks To Ditch In 2015
    What Are The Stock Buyback Benefits For Investors?
    The Eerie Link Between The Federal Reserve And The Sinking Of The Titanic
    What The $16.6 Billion Nokia Merger Means For Investors Today
    New Salmon Is The First GM Animal Approved For Sale As Food
    Wal-Mart Scrimped On Hiring As Store Space Grew Rapidly
    Aetna Says Individual Obamacare Business Performing As Expected

    This Technology Is Already Changing The World

    Nanotechnology usually makes investors’ eyes glaze over.

    It’s one of those abstract, overhyped concepts that you’ve heard about but can’t really generate enough understanding to effectuate any enthusiasm.

    I get it.

    But this field of science is as revolutionary as chemistry was during the 20th century. You know, antibiotics, biotech, preservatives, plastics, super materials, electronics — that kind of boring stuff.

    For example, here’s news in of a Colorado-based biotech firm that is getting solid results killing cancerous tumors:

    Actium BioSystems disclosed today that its novel system platform, ACT, for selectively delivering controlled hyperthermia as an adjuvant to chemotherapy, has been validated via in vivo studies by two independent authorities, including Duke University Medical Center and a contract research facility.

    Actium is now preparing for safety and pharmacokinetic studies to support an application to the FDA for permission to commence First-In-Human clinical studies as soon as possible.

    The in vivo studies successfully demonstrated that Actium technology is able to selectively achieve therapeutic temperatures in the bladder using an intravesical (in the bladder) nanoparticle-mediated hyperthermia approach. It has been known for many years that heat weakens and kills cancer. But heat also affects normal, healthy tissue the same as cancer cells—except that low-temperature heat, from the normal body temperature of 37°C (98.6°F) to less than about 42°C, has little effect on healthy tissue, but can weaken and kill cancer cells. This is the basic concept of treating cancer with low-temperature heat, called hyperthermia.

    And thanks to new techniques to see on such a tiny scale, stories like this one in NewScientist are becoming practically commonplace:

    Delftia acidovorans lives in sticky biofilms that form on top of gold deposits, but exposure to dissolved gold ions can kill it. That’s because although metallic gold is unreactive, the ions are toxic.

    To protect itself, the bacterium has evolved a chemical that detoxifies gold ions by turning them into harmless gold nanoparticles. These accumulate safely outside the bacterial cells.

    “This could have potential for gold extraction,” says Nathan Magarvey of McMaster University in Hamilton, Ontario, who led the team that uncovered the bugs’ protective trick. “You could use the bug, or the molecules they secrete.”

    And then there’s this story that appeared on, a site that provides news about humans’ growing union with artificial intelligence and technology. Two reputable, publicly traded companies are working on printing human tissue and organs:

    3D printing technology is hot and getting hotter. Whereas once 3D printers were limited to a few select materials, these days inputs include metal, plastic, glass, wood, and—human cells? Bet you didn’t see that coming. (Actually, if you’re a regular here, you probably did.) Bioprinting firm, Organovo, isn’t anywhere near 3D printing a hand or heart. But a recently announced partnership with 3D modeling software giant Autodesk (maker of AutoCAD) might speed things up a bit.

    We first encountered Organovo in 2009. The firm introduced the NovoGen bioprinter in 2010—the first of its kind—and has since built ten more. At a cost in the hundreds of thousands of dollars and as yet only rudimentary capability, bioprinting technology is firmly in the developmental stages.

    But its potential is great. Organovo’s machines print human tissue just like ordinary 3D printers—additive construction guided by 3D computer models—but instead of inert materials they deposit living cells amid a simultaneously printed gel scaffold.

    Already bioprinters are capable of printing small parts, like arteries or knee cartilage. And in the near term, the most likely use is in drug testing—an $11 billion market in itself.

    But eventually (years from now) researchers hope to print, not just the piston, but the entire engine—a new heart or lung—customized and made entirely from a patient’s own tissue, limiting the probability of rejection by the body and doing away with long and uncertain waiting periods for donors.

    But it isn’t coming. It’s here now.

    These stories all have one thing in common: None of the advancements would be possible if researchers did not have access to equipment and technology that would allow them to observe, measure and build and manipulate objects on a molecular scale.

    In short, none would be possible without nanotechnologies.

    These kinds of science fiction stories are becoming less and less outrageous. The discovery of penicillin was a stunning achievement; yet, over the years, antibiotics were commonplace. It’s the same kind of thing. Growing and printing tissue sounds outrageous; but 40 years from now, few people will even blink at the concept.

    Where To Look

    Your best strategy is the venture capital approach: take small positions in various companies and hope for a few winners that dwarf the losers.

    The other, complementary strategy is to buy shovel sellers, not gold miners. Buy the ones that sell the new products and equipment that all the new tech players will need to exploit the new wave of advancements.

    With that in mind, here are a handful of interesting plays now in various spaces where nanotechnologies are kicking out some compelling products.

    CVD Equipment Corporation (CVV) is a small, specialized chemical vapor deposition (CVD) company with a division that specializes in building nanotech CVD equipment for research labs in the academic and corporate sectors. It also provides the expertise and training elements for the equipment, or will contract out for research and development. Its business continues to grow despite the harsh economic times.

    Of all the microscopy companies to choose from, I’ve always been partial to FEI Company (FEIC). You can’t do anything at the nano level unless you can see it. And FEI builds the equipment that allows researchers to see what’s going on. It’s one of the shovel sellers.

    Starpharma Holdings Limited (SPHRY) is one of the gems of Australia’s high tech community. This company is a major player in the dendrimer space with some major products in the U.S. Food and Drug Administration’s Phase II and Phase III trials. It also has great exposure in Asian markets.

    Inovio Pharmaceuticals, Inc. (INO) is a vaccine maker that has bumped up a notch synthetic DNA-based vaccines. It has a very promising stable of vaccines in trials, including a universal influenza vaccine, one for Hepatitis C, another for cervical cancer, etc. It just got a nice write-up in Nature Biotechnology.

    On the 3D-printing side, Autodesk Inc. (ADSK), Organovo Holdings Inc. (ONVO)and 3D Systems Corp. (DDD) are worth watching. I like the latter the best, but this sector has had quite a run; it’s become the poster child for nanotech. Be patient and wait for a pullback.

    — GS Early

    Discuss this Story:

    Comment Policy: We encourage open discussion. Comments including racist statements, profanity, name calling or spam will be removed at our discretion. We use filters for spam protection. If your comment does not appear it is likely because it violates the policy.

    Oil Trades Near Three-month Low As Excess Supply Takes Toll
    Number Of $5 Billion-plus Takeover Deals Hits Record
    Investor Gabelli Joins Millennials Cutting The Cable Cord
    Gap Cuts Full-year Profit Forecast As Dollar Weighs
    This Is How GOLD Acted During Past Rising Rate Cycles
    Tumbling Treasury Yields Signal Possible Fed ‘Policy Error’ Being Priced In
    WTI Tumbles Back Below $40, Goldman Warns Risk Of “Sharp Leg Lower”
    Former Subway Pitchman Jared Fogle Is About To Be Sentenced
    This Is The Biggest Diamond Found In More Than A Century
    What ISIS ‘Blood Oil’ Really Means For Oil Markets
    The Day Before Thanksgiving Actually Isn’t The Busiest Time To Fly
    Gender Equality Is Now Better In Rwanda Than In The US
    Anonymous Could Hobble ISIS By Hacking PlayStation Consoles
    The Best Advice If You Find Yourself In A Terror Attack: Do Not Play Dead
    Not Much Evidence Mass Surveillance Works
    Home Depot & Lowes Avoid The Retail Bloodbath With Strong Earnings
    It’s REIT Time: Stock Up Durable Dividends Now
    A Global Financial Literacy Test Finds That Just 57% Of Adults In U.S. Are Financially Literate
    Starboard Asks Yahoo To Drop Alibaba Stake Spinoff Plans
    Oil Slides Again As Focus Returns To Heavy Glut
    Best Buy Comparable Sales Miss On Low Demand For Mobile Devices
    Stock Futures Rise After Fed Minutes Soothe Investor Nerves
    U.S. Consumers Favor Amazon For Online Holiday Shopping
    Pfizer-Allergan Talks Accelerate Amid New Inversion Clamp-down
    Soothing Fed Sounds Send Shares, Emerging Markets Higher
    Crude Tumbles To $40 Handle After DOE Confirms Significant Cushing Inventory Build
    U.S. May Bring Criminal Charges Against JP Morgan, RBS Executives, Prosecutors Pretend
    BlackRock Liquidates Its Macro Hedge Fund Following Worst Loss Since Inception, Surge In Redemptions
    It Will SUNE Be Over: Axiom Says SunEdison “Credit Event Appears More Likely”, Sees Price Dropping To $2/Share
    Read more from Investing...

    Liberty Investor Digest

    Get today's most important
    financial headlines all in
    one place by email!



    Sign Up For Liberty Investor Digest™!

    Get Liberty Investor Digest FREE By Email!

    Input your name and email address in the fields below and get today's most important financial headlines sent straight to you inbox!

    Privacy PolicyYou can opt-out at any time. We protect your information like a mother hen. We will not sell or rent your email address to anyone for any reason.